

Contents

Preface	v
1 Introduction and New Drug Development Process	1
1.1 Introduction	1
1.2 New Drug Development Process	4
1.3 Nonclinical Development	5
1.3.1 Pharmacology	5
1.3.2 Toxicology/Drug Safety	6
1.3.3 Drug Formulation Development	7
1.4 Premarketing Clinical Development	8
1.4.1 Phase I Clinical Trials	8
1.4.2 Phase II/III Clinical Trials	10
1.4.3 Clinical Development for Life-Threatening Diseases	12
1.4.4 New Drug Application	12
1.5 Clinical Development Plan	13
1.6 Postmarketing Clinical Development	14
1.7 Concluding Remarks	16
2 Dose Finding Based on Preclinical Studies	18
2.1 Introduction	18
2.2 Parallel Line Assays	20
2.3 Competitive Binding Assays	20
2.4 Anti-infective Drugs	25
2.5 Biological Substances	25
2.6 Preclinical Toxicology Studies	26
2.7 Extrapolating Dose from Animal to Human	28
3 Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose	30
3.1 Introduction	30
3.2 Basic Concepts	30
3.3 General Considerations for FIH Studies	32

3.3.1	Study Designs	33
3.3.2	Population.....	35
3.4	Dose Selection.....	37
3.4.1	Estimating the Starting Dose in Phase I.....	37
3.4.2	Dose Escalation.....	40
3.5	Assessments.....	42
3.5.1	Safety and Tolerability.....	42
3.5.2	Pharmacokinetics.....	43
3.5.3	Pharmacodynamics.....	43
3.6	Dose Selection for Phase II.....	46
4	Dose-Finding in Oncology—Nonparametric Methods	49
4.1	Introduction.....	49
4.2	Traditional or 3 + 3 Design.....	50
4.3	Basic Properties of Group Up-and-Down Designs.....	51
4.4	Designs that Use Random Sample Size: Escalation and A + B Designs	52
4.4.1	Escalation and A + B Designs.....	52
4.4.2	The 3 + 3 Design as an A + B Design.....	53
4.5	Designs that Use Fixed Sample Size	53
4.5.1	Group Up-and-Down Designs.....	54
4.5.2	Fully Sequential Designs for Phase I Clinical Trials.....	54
4.5.3	Estimation of the MTD After the Trial.....	54
4.6	More Complex Dose-Finding Trials.....	55
4.6.1	Trials with Ordered Groups.....	55
4.6.2	Trials with Multiple Agents.....	56
4.7	Conclusion.....	56
5	Dose Finding in Oncology—Parametric Methods	59
5.1	Introduction.....	59
5.2	Escalation with Overdose Control Design.....	61
5.2.1	EWOC Design.....	61
5.2.2	Example.....	62
5.3	Adjusting for Covariates.....	63
5.3.1	Model.....	63
5.3.2	Example.....	66
5.4	Choice of Prior Distributions.....	68
5.4.1	Independent Priors.....	69
5.4.2	Correlated Priors.....	69
5.4.3	Simulations.....	70
5.5	Concluding Remarks.....	70
6	Dose Response: Pharmacokinetic–Pharmacodynamic Approach	73
6.1	Exposure Response.....	73

6.1.1	How Dose Response and Exposure Response Differ	73
6.1.2	Why Exposure Response is More Informative	73
6.1.3	FDA Exposure Response Guidance	73
6.2	Time Course of Response	74
6.2.1	Action, Effect, and Response	74
6.2.2	Models for Describing the Time Course of Response	74
6.3	Pharmacokinetics	75
6.3.1	Review of Basic Elements of Pharmacokinetics	75
6.3.2	Why the Clearance/Volume Parameterization is Preferred	76
6.4	Pharmacodynamics	77
6.4.1	Review of Basic Elements of Pharmacodynamics	77
6.5	Delayed Effects and Response	77
6.5.1	Two Main Mechanism Classes for Delayed Effects	78
6.6	Cumulative Effects and Response	80
6.6.1	The Relevance of Considering Integral of Effect as the Outcome Variable	80
6.6.2	Why Area Under the Curve of Concentration is not a Reliable Predictor of Cumulative Response	80
6.6.3	Schedule Dependence	81
6.6.4	Predictability of Schedule Dependence	82
6.7	Disease Progress	82
6.7.1	The Time Course of Placebo Response and Disease Natural History	82
6.7.2	Two Main Classes of Drug Effect	83
6.8	Modeling Methods	84
6.8.1	Analysis	84
6.8.2	Mixed Effect Models	85
6.8.3	Simulation	85
6.8.4	Clinical Trial Simulation	85
6.9	Conclusion	86
7	General Considerations in Dose–Response Study Designs	89
7.1	Issues Relating to Clinical Development Plan	89
7.2	General Considerations for Designing Clinical Trials	90
7.2.1	Subject Population and Endpoints	91
7.2.2	Parallel Designs versus Crossover Designs	93
7.2.3	Selection of Control	93
7.2.4	Multiple Comparisons	94
7.2.5	Sample Size Considerations	95
7.2.6	Multiple Center Studies	96
7.3	Design Considerations for Phase II Dose–Response Studies	96
7.3.1	Frequency of Dosing	97
7.3.2	Fixed-Dose versus Dose-Titration Designs	99
7.3.3	Range of Doses to be Studied	100

7.3.4	Number of Doses to be Tested	101
7.3.5	Dose Allocation, Dose Spacing	102
7.3.6	Optimal Designs	103
7.4	Concluding Remarks	103
8	Clinical Trial Simulation—A Case Study Incorporating Efficacy and Tolerability Dose Response	106
8.1	Clinical Development Project Background.....	106
8.1.1	Clinical Trial Objectives.....	107
8.1.2	Uncertainties Affecting Clinical Trial Planning.....	107
8.2	The Clinical Trial Simulation Project	108
8.2.1	Clinical Trial Objectives Used for the CTS Project .	109
8.2.2	The Simulation Project Objective.....	111
8.2.3	Simulation Project Methods 1: Data Models and Design Options.....	111
8.2.4	Simulation Project Methods 2: Analysis and Evaluation Criteria.....	117
8.3	Simulation Results and Design Recommendations	120
8.3.1	Objective 1: Power for Confirming Efficacy.....	120
8.3.2	Objective 2: Accuracy of Target Dose Estimation...	121
8.3.3	Objective 3: Estimation of a Potentially Clinically Noninferior Dose Range.....	121
8.3.4	Trial Design Recommendations.....	124
8.4	Conclusions	125
9	Analysis of Dose–Response Studies—E_{\max} Model	127
9.1	Introduction to the E_{\max} Model.....	127
9.2	Sensitivity of the E_{\max} Model Parameters	129
9.2.1	Sensitivity of the E_0 and E_{\max} Parameters.....	129
9.2.2	Sensitivity of the ED_{50} Parameter	130
9.2.3	Sensitivity of the N Parameter.....	131
9.2.4	Study Design for the E_{\max} Model.....	131
9.2.5	Covariates in the E_{\max} Model.....	133
9.3	Similar Models	134
9.4	A Mixed Effects E_{\max} Model	134
9.5	Examples.....	135
9.5.1	Oral Artesunate Dose–Response Analysis Example	135
9.5.2	Estimation Methodology	137
9.5.3	Initial Parameter Values for the Oral Artesunate Dose–Response Analysis Example.....	138
9.5.4	Diastolic Blood Pressure Dose–Response Example.	139
9.6	Conclusions	141
10	Analysis of Dose–Response Studies—Modeling Approaches	146
10.1	Introduction	146

10.2	Some Commonly Used Dose–Response Models	149
10.2.1	E_{\max} Model	150
10.2.2	Linear in Log-Dose Model.....	151
10.2.3	Linear Model	151
10.2.4	Exponential (Power) Model.....	151
10.2.5	Quadratic Model.....	152
10.2.6	Logistic Model	152
10.3	Estimation of Target Doses.....	153
10.3.1	Estimating the MED in Dose-Finding Example	155
10.4	Model Uncertainty and Model Selection.....	156
10.5	Combining Modeling Techniques and Multiple Testing	160
10.5.1	Methodology.....	160
10.5.2	Proof-of-Activity Analysis in the Dose-Finding Example	162
10.5.3	Simulations	163
10.6	Conclusions	169
11	Multiple Comparison Procedures in Dose Response Studies	172
11.1	Introduction	172
11.2	Identifying the Minimum Effective Dose (MinED).....	172
11.2.1	Problem Formulation.....	172
11.2.2	Review of Multiple Test Procedures	174
11.2.3	Simultaneous Confidence Intervals.....	176
11.3	Identifying the Maximum Safe Dose (MaxSD)	177
11.4	Examples.....	177
11.5	Extensions	180
11.6	Discussion.....	181
12	Partitioning Tests in Dose–Response Studies with Binary Outcomes	184
12.1	Motivation	184
12.2	Comparing Two Success Probabilities in a Single Hypothesis	185
12.3	Comparison of Success Probabilities in Dose–Response Studies.....	188
12.3.1	Predetermined Step-Down Method.....	188
12.3.2	Sample-Determined Step-Down Method.....	190
12.3.3	Hochberg’s Step-up Procedure	194
12.4	An Example Using Partitioning Based Stepwise Methods	195
12.5	Conclusion and Discussion.....	197
13	Analysis of Dose–Response Relationship Based on Categorical Outcomes	200
13.1	Introduction	200
13.2	When the Response is Ordinal.....	201
13.2.1	Modeling Dose–Response	201

13.2.2	Testing for a Monotone Dose–Response Relationship.....	203
13.3	When the Response is Binary.....	207
13.4	Multiple Comparisons.....	210
13.4.1	Bonferroni Adjustment.....	211
13.4.2	Bonferroni–Holm Procedure.....	211
13.4.3	Hochberg Procedure.....	212
13.4.4	Gate-Keeping Procedure.....	212
13.4.5	A Special Application of Dunnett’s Procedure for Binary Response.....	213
13.5	Discussion.....	213
14	Power and Sample Size for Dose Response Studies	220
14.1	Introduction.....	220
14.2	General Approach to Power Calculation.....	221
14.3	Multiple-Arm Dose Response Trial.....	223
14.3.1	Normal Response.....	224
14.3.2	Binary Response.....	227
14.3.3	Time-to-Event Endpoint.....	230
14.4	Phase I Oncology Dose Escalation Trial.....	233
14.4.1	The A + B Escalation without Dose De-Escalation.....	234
14.4.2	The A + B Escalation with Dose De-Escalation.....	236
14.5	Concluding Remarks.....	238
	Index	243